Table 3 Clinicopathological characteristics of RECI2 patients (N = 14)
Patient | Gender | Progression-free interval, mo | OS, mo | % of SEMA6A+ cells | SEMA6A IS | Tumor site |
|---|---|---|---|---|---|---|
Short-Term Responders | ||||||
 1 | F | 12 | 35 | 70% | 2 | Metastasis |
 4 | M | 9 | 16 | 60% | 2 | Lung |
 10 | F | 11 | 18 | 60% | 2 | Lymph node |
50% | 1 | Lung | ||||
 13 | F | 4 | 20 | 60% | 2 | Lung and lymph node |
 14 | F | 8 | 98 | 70% | 2 | Occipital fragment |
 15 | F | 12 | 27 | 50% | 1 | Lung |
Long-Term Responders | ||||||
 2 | M | Ongoing 67 | 68 | 30% | 1 | Middle meatus |
 3 | F | Ongoing 58 | 91 | 30% | 1 | Lymph node |
 5 | M | 39 | 63 | 60% | 2 | Back |
 6 | M | 24 | 50 | 30% | 1 | Lung |
 7 | M | 60 | 75 | 30% | 2 | Face |
 8 | M | Ongoing 82 | 83 | 30% | 2 | Back |
 9 | M | 48 | 86 | 30% | 2 | Lung |
 11 | F | Ongoing 75 | 80 | 30% | 1 | Lymph node |